CN113366019B - Alk2抗体及其使用方法 - Google Patents

Alk2抗体及其使用方法 Download PDF

Info

Publication number
CN113366019B
CN113366019B CN201980085459.7A CN201980085459A CN113366019B CN 113366019 B CN113366019 B CN 113366019B CN 201980085459 A CN201980085459 A CN 201980085459A CN 113366019 B CN113366019 B CN 113366019B
Authority
CN
China
Prior art keywords
seq
alk2
binding fragment
sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980085459.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN113366019A (zh
Inventor
J·S·西拉
J·拉基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keros Therapeutics Inc
Original Assignee
Keros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keros Therapeutics Inc filed Critical Keros Therapeutics Inc
Priority to CN202411099364.XA priority Critical patent/CN118955715A/zh
Publication of CN113366019A publication Critical patent/CN113366019A/zh
Application granted granted Critical
Publication of CN113366019B publication Critical patent/CN113366019B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980085459.7A 2018-10-23 2019-10-23 Alk2抗体及其使用方法 Active CN113366019B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411099364.XA CN118955715A (zh) 2018-10-23 2019-10-23 Alk2抗体及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749463P 2018-10-23 2018-10-23
US62/749463 2018-10-23
PCT/US2019/057679 WO2020086730A1 (en) 2018-10-23 2019-10-23 Alk2 antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411099364.XA Division CN118955715A (zh) 2018-10-23 2019-10-23 Alk2抗体及其使用方法

Publications (2)

Publication Number Publication Date
CN113366019A CN113366019A (zh) 2021-09-07
CN113366019B true CN113366019B (zh) 2024-08-27

Family

ID=70331231

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980085459.7A Active CN113366019B (zh) 2018-10-23 2019-10-23 Alk2抗体及其使用方法
CN202411099364.XA Pending CN118955715A (zh) 2018-10-23 2019-10-23 Alk2抗体及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411099364.XA Pending CN118955715A (zh) 2018-10-23 2019-10-23 Alk2抗体及其使用方法

Country Status (10)

Country Link
US (2) US12331124B2 (https=)
EP (1) EP3870613A4 (https=)
JP (2) JP7512272B2 (https=)
KR (1) KR102919834B1 (https=)
CN (2) CN113366019B (https=)
AU (1) AU2019364415A1 (https=)
BR (1) BR112021007660A2 (https=)
CA (1) CA3116900A1 (https=)
IL (1) IL282424A (https=)
WO (1) WO2020086730A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3870181B1 (en) 2018-10-26 2024-08-14 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
KR20220140802A (ko) 2020-02-11 2022-10-18 리제너론 파아마슈티컬스, 인크. 항-acvr1 항체 및 이의 용도
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
US20250282877A1 (en) * 2021-05-11 2025-09-11 Keros Therapeutics, Inc. Methods of using alk2 and alk3 antibodies
US20250034148A1 (en) * 2021-11-02 2025-01-30 Keros Therapeutics, Inc. Methods of using alk2 inhibitors
WO2024092133A1 (en) * 2022-10-27 2024-05-02 Regeneron Pharmaceuticals, Inc. Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207604A (zh) * 2015-01-30 2017-09-26 学校法人埼玉医科大学 抗alk2抗体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2570458C (en) * 2004-06-09 2014-05-20 Technion Research & Development Foundation Ltd. Antibodies for selective apoptosis of cells
CA2662350A1 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
JP5755635B2 (ja) 2009-03-30 2015-07-29 アクセルロン ファーマ， インコーポレイテッド Ｂｍｐ−ａｌｋ３アンタゴニストおよび骨成長促進のためのその使用
WO2011116212A2 (en) 2010-03-17 2011-09-22 Oncomed Pharmaceuticals, Inc. Bone morphogenetic protein receptor binding agents and methods of their use
WO2012065059A2 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Treatment of atherosclerosis with bmp-alk3 antagonists
JP6601687B2 (ja) * 2014-03-31 2019-11-06 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
US20160075772A1 (en) * 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
WO2016154572A1 (en) * 2015-03-26 2016-09-29 Vanderbilt University Antibody-mediated neutralizaton of ebolaviruses
WO2020118011A1 (en) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
KR20220140802A (ko) 2020-02-11 2022-10-18 리제너론 파아마슈티컬스, 인크. 항-acvr1 항체 및 이의 용도
WO2021257532A1 (en) 2020-06-16 2021-12-23 Incyte Corporation Alk2 inhibitors for the treatment of anemia
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2022098821A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating lymphopenia
WO2022099166A1 (en) 2020-11-09 2022-05-12 Keros Therapeutics, Inc. Methods of treating cardiovascular-related disease
US20250282877A1 (en) 2021-05-11 2025-09-11 Keros Therapeutics, Inc. Methods of using alk2 and alk3 antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207604A (zh) * 2015-01-30 2017-09-26 学校法人埼玉医科大学 抗alk2抗体

Also Published As

Publication number Publication date
JP2022505585A (ja) 2022-01-14
US20250270333A1 (en) 2025-08-28
CA3116900A1 (en) 2020-04-30
WO2020086730A1 (en) 2020-04-30
EP3870613A1 (en) 2021-09-01
EP3870613A4 (en) 2022-08-03
CN113366019A (zh) 2021-09-07
BR112021007660A2 (pt) 2021-08-03
JP2024114820A (ja) 2024-08-23
IL282424A (en) 2021-06-30
CN118955715A (zh) 2024-11-15
JP7512272B2 (ja) 2024-07-08
KR102919834B1 (ko) 2026-01-30
US12331124B2 (en) 2025-06-17
AU2019364415A1 (en) 2021-05-20
KR20210088591A (ko) 2021-07-14
US20210253720A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
CN113366019B (zh) Alk2抗体及其使用方法
US12522646B2 (en) Activin receptor type II chimeras and methods of use thereof
US12440539B2 (en) Methods of using activin receptor type IIB variants
US20230398118A1 (en) Methods of treating cardiovascular-related disease
US20230372390A1 (en) Methods of treating lymphopenia
JP2021518745A (ja) アクチビンｉｉｂ型受容体変異体およびそれらの使用方法
CN115666649B (zh) 一种新型冠状病毒抗体的药物组合物及其用途
JP2013189470A (ja) 神経再生改善のための補体阻害
WO2024102906A2 (en) Activin receptor type ii chimeras and methods of use thereof
US20240228583A1 (en) Activin receptor type ii chimeras and methods of use thereof
US20250188148A1 (en) Methods of administering an activin receptor type iib variant
WO2021189006A1 (en) Methods of using activin receptor type iia variants
US20230406956A1 (en) Methods of treating iron overload
KR20210009197A (ko) 자가면역질환 및 염증성질환 펩타이드 치료제
WO2022240948A1 (en) Methods of using alk2 and alk3 antibodies
HK40119616A (zh) Alk2抗体及其使用方法
US20220133849A1 (en) Compositions and methods for the treatment of smooth muscle dysfunction

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant